Veteran drug hunter adds discovery expertise to technology-enabled biopharma company
Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer. Dr. Hirst brings more than 30 years of expertise in drug discovery across a range of therapeutic areas. He was instrumental in the discovery and development of lorpucitinib and mivatonib, and is co-inventor of vaborbactam, which was approved by the U.S. Food and Drug Administration in combination with meropenem. Most recently, Dr. Hirst served as Interim CSO of Turning Point Therapeutics, which was acquired in August by Bristol Myers Squibb for $4.1 billion.
Latest Aithority Insights : NVIDIA Raises the Standard of Low Code DevOps with the NVIDIA AI Enterprise 2.1
“I’m particularly excited to apply Atomwise’s leading AI-enabled predictive engine to focus on the discovery and optimization of small molecules. I look forward to leading the Atomwise team of talented scientists and applying the company’s unique discovery platform as we advance our molecules through preclinical development and into the clinic.”
“At Atomwise, we continue to reimagine how drug discovery should be done, now that our AI-enabled engine allows us to interrogate novel chemical space and gives us the potential to drug challenging targets,” said Abraham Heifets, Ph.D., Co-Founder and CEO of Atomwise. “Gavin brings deep expertise in structure- and fragment-based drug discovery, and a fantastic track record in driving those initial discoveries to become new medicines to help patients. We are thrilled that he is joining our team.”
AI and ML News: Why SMBs Shouldn’t Be Afraid of Artificial Intelligence (AI)
In his new role, Dr. Hirst will set the company’s strategic vision for drug discovery and provide scientific oversight of Atomwise’s research and development pipeline.
“So much of drug discovery today re-treads known chemistry space or targets. Atomwise’s global machine learning models let us explore new chemical space and find tractable bioactive molecules,” said Dr. Hirst. “I’m particularly excited to apply Atomwise’s leading AI-enabled predictive engine to focus on the discovery and optimization of small molecules. I look forward to leading the Atomwise team of talented scientists and applying the company’s unique discovery platform as we advance our molecules through preclinical development and into the clinic.”
Dr. Hirst has more than 30 years’ experience in the biopharmaceutical industry. He joins Atomwise after serving as Interim Chief Scientific Officer and Senior Vice President of Chemistry at Turning Point Therapeutics, where as he applied structure-based drug design expertise to exploit innovative protein-ligand interactions in the de novo design of precision medicines, including for KRASG12D and the p21 activated kinase (PAK). During previous work at Janssen, Dr. Hirst oversaw a broad portfolio of small-molecule programs targeting a diverse set of autoimmune diseases, including inflammatory bowel disease and psoriasis. He chaired the Global Medicinal Chemistry Council, and was the global chemistry representative for the cheminformatics steering committee. Dr. Hirst guided his teams to deliver a number of clinical-stage assets, such as the Pan-JAK family selective inhibitor lorpucitinib, now in clinical development for the treatment of familial adenomatous polyposis, a form of colorectal cancer. Earlier, he was Vice President of Discovery Research, directing immunology, oncology, and metabolic diseases at Takeda, delivering multiple INDs, most notably mivatonib, a SYK inhibitor, now in phase II for DLBCL and other non-Hodgkin’s lymphomas.
Future of AI-driven Customer Relationship: Microsoft’s Viva Sales and the Future of AI-driven Customer Relationship and Experience Management
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.